Yahoo
HKSE - Delayed Quote HKD

Giant Biogene Holding Co., Ltd. (2367.HK)

20.660 -0.520 (-2.46%)
At close: November 6 at 4:08:50 PM GMT+8
Chart Range Bar
Loading chart for 2367.HK
  • Previous Close 21.180
  • Open 20.760
  • Bid 20.600 x --
  • Ask 20.600 x --
  • Day's Range 20.500 - 21.140
  • 52 Week Range 19.340 - 41.320
  • Volume 2,632,587
  • Avg. Volume 3,928,039
  • Market Cap (intraday) 21.935B
  • Beta (5Y Monthly) 0.80
  • PE Ratio (TTM) 11.81
  • EPS (TTM) 1.750
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.62 (2.99%)
  • 1y Target Est 36.49
  • Moby Rating Neutral

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products. In addition, it provides aesthetic services. The company was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

www.xajuzi.com

2,319

Full Time Employees

December 31

Fiscal Year Ends

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2367.HK
34.64%
HANG SENG INDEX (^HSI)
4.48%

1-Year Return

2367.HK
43.24%
HANG SENG INDEX (^HSI)
7.57%

3-Year Return

2367.HK
36.82%
HANG SENG INDEX (^HSI)
36.26%

5-Year Return

2367.HK
20.54%
HANG SENG INDEX (^HSI)
1.56%

Analyst Insights

View More

Analyst Price Targets

25.00
36.49 Average
20.660 Current
46.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    31.42%

  • Return on Assets (ttm)

    9.80%

  • Return on Equity (ttm)

    18.01%

  • Revenue (ttm)

    5.32B

  • Net Income Avi to Common (ttm)

    1.67B

  • Diluted EPS (ttm)

    1.750

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.4B

  • Total Debt/Equity (mrq)

    0.13%

  • Levered Free Cash Flow (ttm)

    -183.86M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: